

Literatur zum Thema

Bechrakis NE et al. 2021

Uveal melanoma – standardized procedure in diagnosis, therapy and surveillance.

Klin Monatsbl Augenheilkd 2021; 238: 761-772

<https://doi.org/10.1055/a-1534-0198>

Carvajal RD et al. 2022

Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.

Nat Med 2022; 28: 2364-2373

<https://doi.org/10.1038/s41591-022-02015-7>

Hassel J et al. 2023

Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp.

Eur J Cancer 2023;

<https://doi.org/10.1016/j.ejca.2023.112986>

Howlett S et al. 2023

Tebentafusp: a first-in-class treatment for metastatic melanoma.

Ther Adv Med Oncol 2023; 15: 1-12

<https://doi.org/10.1177/17588359231160140>

Nathan P et al. 2021

Overall survival benefit with tebentafusp in metastatic uveal melanoma.

N Engl J Med 2021; 385: 13.

<https://doi.org/10.1056/NEJMoa2103485>

Petzold A et al. 2023

Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment.

Cancer Treat Rev 2023; 115, 102543

<https://doi.org/10.1016/j.ctrv.2023.102543>

Seth R et al. 2022

Systemic therapy for melanoma: ASCO guideline rapid recommendation update.

J Clin Oncol 2022; 40: 2375-2377

<https://ascopubs.org/doi/10.1200/JCO.22.00944>